Bleeding disorders:

Indications for: AMICAR TABLETS

Bleeding associated with fibrinolysis.

Adult Dosage:

Initially 5g during 1st hour, then 1g/hour for 8 hours or until bleeding is controlled.

Children Dosage:

Not recommended.

AMICAR TABLETS Contraindications:

Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin.

AMICAR TABLETS Warnings/Precautions:

Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers.

AMICAR TABLETS Classification:


AMICAR TABLETS Interactions:

Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk.

Adverse Reactions:

Bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy.

Drug Elimination:

Renal excretion is the primary route of elimination. Terminal elimination half-life is approximately 2 hours.

Generic Drug Availability:


How Supplied:

Tabs—30; Oral soln—236.5mL